Skip to main content
. Author manuscript; available in PMC: 2020 Jun 16.
Published in final edited form as: J Neurooncol. 2017 Dec 20;137(2):303–311. doi: 10.1007/s11060-017-2718-z

Figure 1|.

Figure 1|

Kaplan-Meier Overall Survival Analysis for Primary Gliosarcoma versus Glioblastoma

A. mOS for primary gliosarcoma (n=22) versus GBM (n=451) (11.0 versus 14.8 months, log-rank p=NS). B. mOS among patients treated with temozolomide-based chemoradiotherapy (11.0 months GSM, n=14 versus 17.3 months GBM, n=256) (log-rank p=0.006)